Browse

You are looking at 1 - 10 of 2,623 items for

  • Refine by access: All content x
Clear All
Dingwen Liu Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Dingwen Liu in
Google Scholar
PubMed
Close
,
Liang Zhou Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Liang Zhou in
Google Scholar
PubMed
Close
,
Cheng Li Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Cheng Li in
Google Scholar
PubMed
Close
,
Youyou Li Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Youyou Li in
Google Scholar
PubMed
Close
,
Jiahao Liu Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Jiahao Liu in
Google Scholar
PubMed
Close
,
Lei Zhou Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Lei Zhou in
Google Scholar
PubMed
Close
,
Jin Tang Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Jin Tang in
Google Scholar
PubMed
Close
,
Wei Xiong Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Wei Xiong in
Google Scholar
PubMed
Close
, and
Long Wang Department of Urology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

Search for other papers by Long Wang in
Google Scholar
PubMed
Close

This study provides a comprehensive analysis of global, continental, and national trends in the prevalence and mortality of prostate cancer (PC), breast cancer (BC), and thyroid cancer (TC). Utilizing 2021 Global Burden of Diseases (GBD2021) data, prevalence and death rates for 2021 were examined, with temporal trends from 1990 to 2021 analyzed via Joinpoint regression. Annual percentage change (APC) and average APC (AAPC) were calculated with 95% CI. Distributive inequalities were quantified using the slope index of inequality and concentration index. In 2021, PC, BC, and TC showed higher global age-standardized prevalence rates (ASPR) in Europe and America compared to Africa and Asia, while higher age-standardized death rates (ASDR) for PC and BC were noted in Africa. Over the study period, significant global increases in ASPR were observed for PC (AAPC = 0.78, 95% CI: 0.67 to 0.89), BC (AAPC = 0.31, 95% CI: 0.24 to 0.37), and TC (AAPC = 1.42, 95% CI: 1.31 to 1.52). Conversely, ASDR significantly decreased for PC (AAPC = −0.83, 95% CI: −0.92 to −0.74), BC (AAPC = −0.48, 95% CI: −0.56 to −0.39), and TC (AAPC = −0.23, 95% CI: −0.29 to −0.17). Variations were observed across continents and time periods, affecting 204 countries and territories. Higher Social Development Index (SDI) levels were associated with a more pronounced burden of these cancers. The findings highlight significant global heterogeneity in prevalence, death rates, and temporal trends of endocrine cancers, with important implications for epidemiology and public health policies.

Restricted access
Tugba Barlas Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Tugba Barlas in
Google Scholar
PubMed
Close
,
Osman Sutcuoglu Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Osman Sutcuoglu in
Google Scholar
PubMed
Close
,
Orhun Akdogan Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Orhun Akdogan in
Google Scholar
PubMed
Close
,
Fusun Balos Toruner Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Fusun Balos Toruner in
Google Scholar
PubMed
Close
,
Mujde Akturk Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Mujde Akturk in
Google Scholar
PubMed
Close
,
Nuriye Ozdemir Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Nuriye Ozdemir in
Google Scholar
PubMed
Close
,
Ozan Yazici Department of Medical Oncology, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Ozan Yazici in
Google Scholar
PubMed
Close
, and
Alev Eroglu Altinova Department of Endocrinology and Metabolism, Gazi University, Faculty of Medicine, Ankara, Turkey

Search for other papers by Alev Eroglu Altinova in
Google Scholar
PubMed
Close

Immune checkpoint inhibitors (ICIs) can trigger immune-related adverse events (irAEs). The appearance pattern of irAEs, who is prone to them, and their mechanisms are still uncertain. In this study, we aimed to monitor patients initiated on ICIs for endocrinological aspects and to investigate the potential predictive markers in the development of endocrine-irAEs. The study prospectively included 43 patients with metastatic disease scheduled for anti-PD-1/L1 therapy. Endocrinological follow-up was conducted at specified intervals as well as in response to any additional reported complaints. Serum concentrations of CXCL10, IL-1beta, and IL-17A were measured prior to ICI and during the endocrine-irAEs. A total of 39.5% of the patients experienced endocrine-irAEs, with a median onset time of 3 months. Among patients, 34.9% developed thyroid-related adverse events, and 4.6% experienced hypophysitis. Thyroid autoantibodies were associated with a higher incidence of thyroid-related irAEs (P = 0.004). In the irAE group, median pre-ICI CXCL10 and baseline thyroid stimulating hormone (TSH) levels were significantly higher, baseline total testosterone level in men was lower than in the non-irAE group (P < 0.05), whereas IL-1beta and IL-17A levels did not differ (P > 0.05). Serum CXCL10, IL-1beta, and IL-17A concentrations did not differ significantly pre-ICI and during adverse events (P > 0.05). Pre-ICI CXCL10 concentration was correlated positively with anti-TPO levels in patients with at least one thyroid autoantibody positivity (r = 0.706, P = 0.01) and negatively with baseline total testosterone level of men (r = 0.509, P = 0.002). Our results suggest that higher pre-ICI serum CXCL10 and TSH levels might have a predictive role in the development of endocrinopathies. Besides, baseline thyroid antibody measurements could be beneficial in predicting thyroid dysfunction.

Restricted access
Rushabh Gujarathi Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA

Search for other papers by Rushabh Gujarathi in
Google Scholar
PubMed
Close
,
Sara Abou Azar Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA

Search for other papers by Sara Abou Azar in
Google Scholar
PubMed
Close
,
Joseph Tobias Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA

Search for other papers by Joseph Tobias in
Google Scholar
PubMed
Close
,
Blase N Polite Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA

Search for other papers by Blase N Polite in
Google Scholar
PubMed
Close
,
Namrata Setia Department of Pathology, University of Chicago, Chicago, Illinois, USA

Search for other papers by Namrata Setia in
Google Scholar
PubMed
Close
,
Nicholas Feinberg Department of Radiology, University of Chicago, Chicago, Illinois, USA

Search for other papers by Nicholas Feinberg in
Google Scholar
PubMed
Close
,
Daniel E Appelbaum Department of Radiology, University of Chicago, Chicago, Illinois, USA

Search for other papers by Daniel E Appelbaum in
Google Scholar
PubMed
Close
,
Xavier M Keutgen Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA

Search for other papers by Xavier M Keutgen in
Google Scholar
PubMed
Close
, and
Chih-Yi Liao Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA

Search for other papers by Chih-Yi Liao in
Google Scholar
PubMed
Close

Pre-clinical data suggest that mutations in the MEN1, DAXX, and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor radionuclide therapy (PRRT) and those mutations in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We analyzed tissue-based next generation sequencing (NGS) assay results and clinicopathologic data from 28 patients with GEP-NETs treated with PRRT. Findings were correlated with progression-free survival (PFS) and objective response rate (ORR). Patients with mutations in MEN1, DAXX, and/or ATRX (n = 13) had a longer median PFS (26.47 vs 12.13 months; P = 0.014) than wild-type (n = 15) patients when adjusted for surgery prior to PRRT, tumor grade, and presence of TP53 mutation. Alterations in MEN1 along with a concurrent mutation in either DAXX or ATRX (n = 6) trended toward longer PFS compared to patients without concurrent mutations (31.53 vs 17.97 months; P = 0.09). ORR was higher in patients with a mutation in MEN1, DAXX, or ATRX (41.67% vs 15.38%). In pancreatic NET patients, these target mutations also showed a longer PFS (28.43 vs 9.83 months; P = 0.04). TP53 alterations showed a shorter PFS than wild-type cases (11.17 vs 20.47 months; P = 0.009). Mutations in MEN1/DAXX/ATRX are associated with improved PFS in patients with GEP-NETs receiving PRRT and might be used as a biomarker for treatment response.

Restricted access
A Mohamed Division of Hematology and Medical Oncology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by A Mohamed in
Google Scholar
PubMed
Close
,
M Trybula Division of Hematology and Medical Oncology, UH Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by M Trybula in
Google Scholar
PubMed
Close
,
S L Asa Department of Medicine, UH Seidman Cancer Center Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA

Search for other papers by S L Asa in
Google Scholar
PubMed
Close
,
T R Halfdanarson Division of Medical Oncology, Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA

Search for other papers by T R Halfdanarson in
Google Scholar
PubMed
Close
, and
M B Sonbol Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Phoenix, Arizona, USA

Search for other papers by M B Sonbol in
Google Scholar
PubMed
Close

The classification and management of neuroendocrine neoplasms (NENs) arising in the tubular gastrointestinal (GI) tract and pancreas have significantly evolved over the last decades. In the latest WHO classification published in 2022, NENs are separated regardless of their primary origin into two main groups: well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The substantial changes in the grading system changed the definition of grade 3 to include high-grade well-differentiated NETs (G3-NETs), and poorly differentiated NECs (-NECs). Although these two subgroups are considered high grades with Ki-67 >20%, they have different genomic profiles, prognosis, and clinical behavior, which critically influence their treatment strategies. The available clinical trial data to guide therapy of these high-grade subgroups are extremely limited, which impacts their management. In this review, we will summarize the current advances in the multidisciplinary approach for the management of high-grade gastroenteropancreatic NENs (GEP-NENs) including G3-NETs and NECs.

Restricted access
Andrew McDonald Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Andrew McDonald in
Google Scholar
PubMed
Close
,
Vaidehi Avadhani Grady Memorial Hospital, Atlanta, Georgia, USA

Search for other papers by Vaidehi Avadhani in
Google Scholar
PubMed
Close
,
Gabriela Oprea-Ilies Grady Memorial Hospital, Atlanta, Georgia, USA

Search for other papers by Gabriela Oprea-Ilies in
Google Scholar
PubMed
Close
,
Katerina Zakka Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Katerina Zakka in
Google Scholar
PubMed
Close
,
Gregory B Lesinski Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Gregory B Lesinski in
Google Scholar
PubMed
Close
,
Olumide B Gbolahan Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Olumide B Gbolahan in
Google Scholar
PubMed
Close
, and
Olatunji Alese Winship Cancer Institute at Emory University, Atlanta, Georgia, USA

Search for other papers by Olatunji Alese in
Google Scholar
PubMed
Close

Gastroenteropancreatic high-grade (HG) neuroendocrine carcinoma (GEP-NEC) is an aggressive malignancy with limited treatment options and increasing incidence in the United States. Due to the rarity of the cancer and heterogeneity of the primary tumor location, data on GEP-NEC oncogenesis and its interaction with the host immune system are limited. A greater understanding of GEP-NEC and its tumor microenvironment (TME) would benefit efforts to develop more effective targeted therapies and rationally adapt immunotherapy to this disease. In this study, we profiled the expression of 770 unique genes using 21 biopsy samples from patients with GEP-NEC using the NanoString nCounter PanCancer IO 360 platform. Our results show several trends evident within the GEP-NEC TME. Greater expression of genes indicative of immune cell infiltration was present within the TME of patients <60 years of age and in patients with greater overall survival (OS). Tumors from patients with non-pancreatic NEC had diminished MHCII expression compared to pancreatic NEC, suggesting more prominent adaptive immune responses in the pancreatic GEP-NEC subtype. Patients with a >6 months OS had tumors with elevated NK cell gene signatures compared to patients with poor survival. Further, the analysis revealed numerous differentially expressed genes based on patient age, tumor location, response to treatment, and OS, which warrant future validation for assessing the relationship with clinical outcomes in patients.

Restricted access
Adam I Kaplan Kolling Institute of Medical Research, The University of Sydney, Sydney, Australia
Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia

Search for other papers by Adam I Kaplan in
Google Scholar
PubMed
Close
,
Trisha Dwight Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

Search for other papers by Trisha Dwight in
Google Scholar
PubMed
Close
,
Catherine Luxford Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

Search for other papers by Catherine Luxford in
Google Scholar
PubMed
Close
,
Diana E Benn Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

Search for other papers by Diana E Benn in
Google Scholar
PubMed
Close
, and
Roderick J Clifton-Bligh Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia
Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

Search for other papers by Roderick J Clifton-Bligh in
Google Scholar
PubMed
Close

Phaeochromocytomas and paragangliomas (collectively termed PPGL) are rare yet highly heritable neuroendocrine tumours, with over one-third of cases associated with germline pathogenic variants (PVs) in numerous genes. PVs in the succinate dehydrogenase subunit-A gene (SDHA) were initially implicated in hereditary PPGL in 2010, and SDHA has since become an important susceptibility gene accounting for up to 2.8% of cases. However, it remains poorly understood, particularly regarding the clinical nature of SDHA PPGL, rates of recurrence and metastasis, and the nature of metastatic disease. We present a narrative review of SDHA-related PPGL, covering pathophysiology, relevance to current clinical practice, and considerations for clinical genetics. We analyse a pool of 107 previously reported cases of SDHA-associated PPGL to highlight the spectrum of SDHA-related PPGL. Our analysis demonstrates that SDHA PPGL occurs across a wide age range (11–81 years) and affects men and women equally. SDHA PPGL typically presents as single tumours (91%), usually occurring in the head and neck (46%) or abdomen (43%, including 15% with phaeochromocytomas). Metastatic disease was reported in 25.5% of cases, with bone (82%) and lymph nodes (71%) being the most common sites of metastasis, often identified many years after the initial diagnosis. A family history of SDHA-related neoplasia was rare, reported in only 4% of cases. Understanding the clinical nature and risks associated with SDHA PVs is essential for facilitating the optimal management of patients and their families.

Open access
Marta García-Goñi Department of Endocrinology and Nutrition, University of Navarra, Pamplona, Spain

Search for other papers by Marta García-Goñi in
Google Scholar
PubMed
Close
,
Beatriz Vázquez Gutiérrez Department of Endocrinology and Nutrition, University of Navarra, Pamplona, Spain

Search for other papers by Beatriz Vázquez Gutiérrez in
Google Scholar
PubMed
Close
,
Miguel F Sanmamed Department of Oncology, University of Navarra, Pamplona, Spain

Search for other papers by Miguel F Sanmamed in
Google Scholar
PubMed
Close
,
Salvador Martín-Algarra Department of Oncology, University of Navarra, Pamplona, Spain
IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain

Search for other papers by Salvador Martín-Algarra in
Google Scholar
PubMed
Close
,
José Luis Pérez-Gracia Department of Oncology, University of Navarra, Pamplona, Spain
IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain

Search for other papers by José Luis Pérez-Gracia in
Google Scholar
PubMed
Close
,
María Olmedo Department of Oncology, University of Navarra, Pamplona, Spain

Search for other papers by María Olmedo in
Google Scholar
PubMed
Close
,
Estefanía Chumbiauca Department of Endocrinology and Nutrition, University of Navarra, Pamplona, Spain

Search for other papers by Estefanía Chumbiauca in
Google Scholar
PubMed
Close
,
Nerea Martín-Calvo IdiSNA (Instituto de investigación en la Salud de Navarra), Pamplona, Spain
Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain
CIBER de Fisiopatología de la Obesidad y la Nutrición, Pamplona, Spain

Search for other papers by Nerea Martín-Calvo in
Google Scholar
PubMed
Close
, and
Juan C Galofré Department of Endocrinology and Nutrition, University of Navarra, Pamplona, Spain
Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain

Search for other papers by Juan C Galofré in
Google Scholar
PubMed
Close

A common immune-related adverse event (irAE) with immune checkpoint inhibitors (ICIs) is thyroid dysfunction (TD-irAEs). The clinical presentation can be varied, and its association with prognosis remains unclear. We investigated the characteristics of TD-irAEs and their association with clinical outcomes among cancer patients treated with ICIs in a real-life setting. Response to treatment was assessed using RECIST v1.1. We calculated the probability of recurrence and survival associated with TD-irAEs using multivariable-adjusted regression and Cox proportional hazards models. In this single-center retrospective analysis, we included 238 patients (72% male) with a median age of 69.5 years. Primary tumors were melanoma (23.1%), lung (60.5%), or urothelial cancer (16.4%), treated with atezolizumab (23.1%), pembrolizumab (44.5%), ipilimumab (0.4%), and/or nivolumab (25.6%). Seventy (29%) patients developed TD-irAEs in a median time of 69 days (41–181). The incidence of TD-irAEs with combination therapy was higher than with monotherapy (67% vs 6.3%, P = 0.011). TD-irAE patients showed a higher objective response rate (ORR) than those without TD-irAEs (60% vs 42.3%, P = 0.013) and longer overall survival (OS) 45 vs 16 months, P < 0.006. Patients who developed TD-irAEs had a relative reduction of 77% (OR 0.23, 95% CI 0.11–0.47) in the risk of progression and of 47% in the risk of mortality (HR 0.53, 95% CI 0.36–0.80), independent of age, sex, primary tumor, or ICI regimen. TD-irAEs occur in nearly 30% of our patients receiving ICIs. In our analysis, TD-irAEs appeared to be associated with higher ORR and longer OS and showed a reduction in the risk of progression and mortality.

Restricted access
Liyan Zhou Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Liyan Zhou in
Google Scholar
PubMed
Close
,
Guiying Bai Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Guiying Bai in
Google Scholar
PubMed
Close
,
Yue Song Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yue Song in
Google Scholar
PubMed
Close
,
Xiaohui Liu Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Xiaohui Liu in
Google Scholar
PubMed
Close
,
Xiaoqing Li Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Xiaoqing Li in
Google Scholar
PubMed
Close
,
Yilin Deng Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yilin Deng in
Google Scholar
PubMed
Close
,
Yiran Si Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yiran Si in
Google Scholar
PubMed
Close
,
Yehui Shi Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Yehui Shi in
Google Scholar
PubMed
Close
, and
Hongli Li Department of Phase I Clinical Trial, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Search for other papers by Hongli Li in
Google Scholar
PubMed
Close

Scientific evidence has linked diabetes to a higher incidence and increased aggressiveness of breast cancer; however, mechanistic studies of the numerous regulators involved in this process are insufficiently thorough. Advanced glycation end products (AGEs) play an important role in the chronic complications of diabetes, but the mechanisms of AGEs in breast cancer are largely unexplored. In this study, we first demonstrate that high AGE levels in breast cancer tissues are associated with the diabetic state and poor patient outcomes. Furthermore, AGEs interact with the receptor for AGEs (RAGE) to promote breast cancer cell migration and invasion. Mechanistically, based on RNA sequencing (RNA-seq) analysis, we reveal that growth arrest and DNA damage gene 45α (GADD45α) is a vital protein upregulated by AGEs through a P53-dependent pathway. Next, GADD45α recruits thymine DNA glycosylase for base excision repair to form the demethylation complex at the promoter region of MMP-9 and enhance MMP-9 transactivation through DNA demethylation. Overall, our results indicate a critical regulatory role of AGEs in patients with breast cancer and diabetes and reveal a novel mechanism of epigenetic modification in promoting breast cancer metastasis.

Restricted access
Marta Villanova M Villanova, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, United States

Search for other papers by Marta Villanova in
Google Scholar
PubMed
Close
,
Sara M. Tolaney S Tolaney, Medical Oncology, Dana-Farber Cancer Institute, Boston, United States

Search for other papers by Sara M. Tolaney in
Google Scholar
PubMed
Close
, and
Le Min L Min, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, United States

Search for other papers by Le Min in
Google Scholar
PubMed
Close

Pembrolizumab-related thyroid dysfunction has been associated with better outcomes in metastatic cancer patients. This study aims to examine the outcomes [pathological Complete Response (pCR) and event-free survival (EFS)] in early-stage triple negative breast cancer (TNBC) patients receiving preoperative therapy who developed pembrolizumab-related thyroid dysfunction. Patients were divided into four groups based on the occurrence or not of pembrolizumab-related thyroid dysfunction (group A and D, respectively) and, in case of pre-existing thyroid disorder, based on the need of levothyroxine start/adjustment or not (group B and C, respectively). pCR and EFS in groups ABC were compared to the ones in group D. Sixty-four early-stage TNBC patients were included and the median follow-up was 16.5 months (IQR 12.0-23.8). Multiple patterns of thyroid irAEs were observed (overt hypothyroidism in 56.3%, subclinical thyrotoxicosis in 28.1%, overt thyrotoxicosis and subclinical hypothyroidism in 21.9%, and 21.9% of patients). No statistical difference was found in pCR (chi-square test, p=0.611) comparing groups ABC to group D. The median EFS in groups ABC and in group D were 16.5 (IQR 12.0-24.0) and 16.0 (IQR 12.0–22.3) months, respectively (log-rank test, p=0.671). The percentage of patients obtaining pCR was 85.7% in patients developing pembrolizumab–related overt thyrotoxicosis and 42.1% in remaining patients (Chi-square test, p=0.036). The EFS was 16.0 months (IQR 12.0-25.0) in patients developing pembrolizumab–related overt thyrotoxicosis and 16.0 months (IQR 12.0-23.5) in the remaining patients (log-rank test, p=0.494). In conclusion, multiple patterns of pembrolizumab-related thyroid dysfunction occurs in early-stage TNBC. Patients developing pembrolizumab-related overt thyrotoxicosis are more likely to achieve pCR.

Restricted access
Neha Venkatesh N Venkatesh, N/A, Baylor College of Medicine, Houston, United States

Search for other papers by Neha Venkatesh in
Google Scholar
PubMed
Close
,
Rebecca S. Tidwell R Tidwell, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Rebecca S. Tidwell in
Google Scholar
PubMed
Close
,
Yao Yu Y Yu, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Yao Yu in
Google Scholar
PubMed
Close
,
Ana Aparicio A Aparicio, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Ana Aparicio in
Google Scholar
PubMed
Close
,
Amado J. Zurita A Zurita, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Amado J. Zurita in
Google Scholar
PubMed
Close
,
Sumit K Subudhi S Subudhi, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Sumit K Subudhi in
Google Scholar
PubMed
Close
,
Bilal A. Siddiqui B Siddiqui, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Bilal A. Siddiqui in
Google Scholar
PubMed
Close
,
Sagar S. Mukhida S Mukhida, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Sagar S. Mukhida in
Google Scholar
PubMed
Close
,
Justin R. Gregg J Gregg, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Justin R. Gregg in
Google Scholar
PubMed
Close
,
Paul G. Corn P Corn, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Paul G. Corn in
Google Scholar
PubMed
Close
,
Efstratios Koutroumpakis E Koutroumpakis, Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Efstratios Koutroumpakis in
Google Scholar
PubMed
Close
,
Jennifer L. McQuade J McQuade, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Jennifer L. McQuade in
Google Scholar
PubMed
Close
,
Daniel E Frigo D Frigo, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Daniel E Frigo in
Google Scholar
PubMed
Close
,
Patrick G. Pilie P Pilie, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Patrick G. Pilie in
Google Scholar
PubMed
Close
,
Chad Huff C Huff, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Chad Huff in
Google Scholar
PubMed
Close
,
Christopher J Logothetis C Logothetis, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Christopher J Logothetis in
Google Scholar
PubMed
Close
, and
Andrew W. Hahn A Hahn, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, United States

Search for other papers by Andrew W. Hahn in
Google Scholar
PubMed
Close

Hormone therapy (HT) to treat prostate cancer is reported to cause adverse changes in body composition. Clinically, interpatient body composition changes are heterogeneous, but the biologic and clinical determinants of body composition toxicity are unknown. Herein, we test the hypothesis that inherited polymorphisms in steroidogenic genes are associated with differential change in body composition after HT. Men with biochemically recurrent prostate cancer (BCR) who received 8 months of LHRH analog (LHRHa) +/- abiraterone acetate (AAP) were eligible if they had: 1) CT imaging of L3 prior to and after treatment, and 2) nucleated cells collected. Cardiometabolic co-morbidities were retrospectively extracted. Body composition was measured using an AI-based segmentation tool. Germline DNA whole exome or genome sequencing was performed. In 162 men treated with 8 months of HT, median skeletal muscle mass (SMMi) loss was 6.6% and subcutaneous adipose gain was 12.3%. Men with type 2 diabetes had higher loss of SMMi after treatment (-11.1% vs. -6.3%, p = 0.003). For the 150 men with germline NGS, SRD5A2 rs523349 genotype was associated with differential loss in skeletal muscle density after HT, (-1.3% vs. -7.1%, p=0.04). In addition, HSD3B1 rs104703 genotype was associated with decreased baseline visceral adipose tissue (63.0 cm2/m2 vs. 77.9, p=0.05). In men with BCR, HT induced notable loss of skeletal muscle and increased subcutaneous adipose tissue. An inherited polymorphism in SRD5A2 and T2DM were associated with differential skeletal muscle toxicity. These findings suggest that inherited polymorphisms may contribute to the body composition toxicity observed with HT.

Restricted access